Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Pancreatic Cancer statistics
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
With an FDA orphan drug designation now granted to IGNK001, clinical trials investigating the agent in acute myeloid leukemia are planned to initiate in the…
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo…
Experiencing guilt after cancer treatment may sound unexpected, but it’s actually quite common. Clinical psychologist Catherine Powers, Ph.D., and senior social work counselor Kendolyn Shankle…
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS…